Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
Status:
Terminated
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
This study is a single site double blinded Phase II study to evaluate the chemopreventative
effectiveness of vismodegib in the treatment of subjects at high risk for developing basal
cell carcinomas (BCC).